Anika Therapeutics, Inc.
ANIK
$14.36
$0.161.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.06% | -1.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.06% | -1.42% | |||
| Cost of Revenue | -6.52% | -11.71% | |||
| Gross Profit | 23.07% | 8.50% | |||
| SG&A Expenses | 1.77% | -2.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.48% | -4.16% | |||
| Operating Income | 119.98% | 22.66% | |||
| Income Before Tax | 134.17% | 43.62% | |||
| Income Tax Expenses | -210.44% | 37.89% | |||
| Earnings from Continuing Operations | 156.72% | 31.68% | |||
| Earnings from Discontinued Operations | -278.37% | 24.96% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 112.54% | 41.34% | |||
| EBIT | 119.98% | 22.66% | |||
| EBITDA | 207.32% | 37.18% | |||
| EPS Basic | 112.69% | 41.57% | |||
| Normalized Basic EPS | 134.57% | 43.86% | |||
| EPS Diluted | 109.72% | 43.01% | |||
| Normalized Diluted EPS | 133.64% | 43.23% | |||
| Average Basic Shares Outstanding | -1.01% | 0.38% | |||
| Average Diluted Shares Outstanding | 1.73% | -0.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||